Monday, May 20, 2024

CDC responds to H5N1 bird flu; From Me, To You campaign; and more - 5/20/2024

Received this email from a friend? Sign up now

CDC Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People
May 20, 2024
This message includes updates on respiratory viruses from CDC.

CDC Responds to H5N1 Bird Flu


A multistate outbreak of highly pathogenic avian influenza (HPAI) A(H5N1) virus has been detected in dairy cattle in the United States. The Centers for Disease Control and Prevention (CDC), the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), state public health and animal health officials, and other partners continue to respond to this outbreak using a One Health approach.
 
H5N1 bird flu has been detected in unpasteurized (raw) milk samples collected from sick cattle on dairy farms during the course of the outbreak investigation. Based on current evidence from FDA, the commercial pasteurized milk supply is considered safe because the pasteurization process is effective in killing H5N1 bird flu. Additionally, milk from sick cows is diverted or destroyed. However, while the risk of consuming raw milk and raw milk products with live H5N1 viruses is not fully known, theoretically, it could infect people with H5N1 bird flu, which can cause serious disease. In general, raw milk and any products made from raw milk can be contaminated with germs that can cause serious illness, hospitalization, or death. Anyone, even healthy adults, can get sick from drinking raw milk. Make the best decision for your health and the health of your family by always choosing pasteurized milk and products made with it.
 
Get weekly updates from CDC: H5N1 Bird Flu: Current Situation Summary

pregnant woman

From Me, To You 


As a new parent, you will share many things with your baby: your wisdom, your love, your excitement, and your joy. Getting recommended vaccinations while you’re pregnant helps your body create protective antibodies (proteins produced by the body to fight off illnesses) that you can pass on to your baby. These antibodies help protect your baby from several illnesses during their first few months of life. Help strengthen your baby’s immunity before they are even born. Talk to a healthcare provider you trust about the vaccines that are right for you during your pregnancy.

covid-19 test

PCR Tests Are the Most Reliable Type of COVID-19 Test 


Testing for COVID-19 can help you decide what to do next, like getting treatment to reduce your risk of severe illness and taking steps to lower your chances of spreading the virus to others. If you are at higher risk for severe COVID-19, talk to your healthcare provider about PCR tests to avoid delayed diagnosis. Don’t delay: Treatment must be started within 5-7 days after you first develop symptoms.

Centers for Disease Control and Prevention

1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348
Questions or Problems  |  Unsubscribe

Wednesday, April 24, 2024

FDA authorizes Pemgarda to help prevent COVID-19 for immunocompromised people

Received this email from a friend? Sign up now

CDC Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People
Respiratory Virus updates - CDC
April 23, 2024
This message includes updates on respiratory viruses from CDC.
mother and daughter on beach

FDA Authorizes Pemgarda to Help Prevent COVID-19 for Immunocompromised People


FDA has authorized a monoclonal antibody to help prevent COVID-19 for people who are moderately or severely immunocompromised, ages 12 and older, and weighing at least 88 pounds. In addition to vaccination, Pemgarda may provide another layer of protection against COVID-19 and can be given at least 2 weeks after receiving a COVID-19 vaccine

A healthcare provider gives Pemgarda as a single intravenous infusion over 60 minutes at a doctor’s office or healthcare facility. If continued protection is needed, additional doses may be given every 3 months.

People who are privately insured or have Medicare part B may receive Pemgarda for free. Talk to your healthcare provider to see if Pemgarda is right for you.

Graphic of man showing his band aid

Acute Cardiac Events in Older Adults Hospitalized for RSV


A new CDC study published in the Journal of the American Medical Association Internal Medicine (JAMA IM) shows that acute cardiac events occur frequently in adults 50 years and older who are hospitalized with respiratory syncytial virus (RSV) infection. Key findings include:

  • Nearly one-quarter experienced an acute cardiac event—most commonly acute heart failure. 
  • Experiencing an acute cardiac event nearly doubled the risk of severe outcomes like ICU admission and death.
  • One in 12 adults with no documented underlying cardiovascular disease experienced an acute cardiac event during their hospitalization for RSV.

Among older adults, RSV can cause up to 160,000 hospitalizations and 10,000 deaths each year. If you are age 60 or older, talk to your healthcare provider about whether the RSV vaccine is right for you. RSV vaccines help protect older adults from severe RSV illness, particularly those with certain chronic medical conditions, those who are elderly or frail, and those living in nursing homes. 

Centers for Disease Control and Prevention

1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348
Questions or Problems  |  Unsubscribe

Thursday, March 14, 2024

COVID-19 Vaccine Recommendation for Older Adults, International Long COVID Awareness Day, and More

Received this email from a friend? Sign up now

CDC Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People
Coronavirus Disease 2019 (COVID-19)
March 14, 2024
This message includes updates on respiratory viruses from CDC.
Picture  of a men and women laughing

Older Adults Now Able to Receive Additional Dose of Updated COVID-19 Vaccine


CDC recommends that adults ages 65 years and older receive an additional updated 2023-2024 COVID-19 vaccine dose. Adults 65 years and older are disproportionately impacted by COVID-19, with more than half of COVID-19 hospitalizations during October 2023 to December 2023 occurring in this age group. The recommendation acknowledges the increased risk of severe disease from COVID-19 in older adults, along with the currently available data on vaccine effectiveness. Data continues to show the importance of vaccination to protect those most at risk for severe outcomes of COVID-19. An additional dose of the updated COVID-19 vaccine may restore protection that has waned since a fall vaccine dose, providing increased protection to adults ages 65 years and older.

Picture  of a men and women laughing

International Long COVID Awareness Day


March 15 is International Long COVID Awareness Day. This year's theme is "Confront Long COVID." It is important to recognize and raise awareness of Long COVID as a real and serious infection-associated chronic condition that has affected millions of people across the United States. CDC and other federal partners and stakeholders are actively working to address gaps in the understanding of Long COVID and the needs of people with Long COVID. Please join us in supporting people with this condition. Together, we can confront Long COVID. 


Picture  of a men and women laughing

CDC study shows effectiveness of RSV immunization for infants 


Early CDC surveillance data show that nirsevimab is 90% effective at preventing hospitalizations associated with respiratory syncytial virus (RSV) in babies. These findings support CDC’s current recommendations for administration of nirsevimab for babies younger than 8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8–19 months at increased risk for severe RSV disease. To reduce the risk of RSV-associated hospitalization, all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab. New or expecting parents should talk to their providers about RSV and make a plan for the 2024-2025 season. 


Picture  of a men and women laughing

2023–2024 Seasonal Flu Vaccine Effectiveness


A new CDC report provides interim vaccine effectiveness (VE) estimates for 2023-2024 flu vaccines in the United States. One VE Network showed:

  • Vaccinated children (6 months-17 years) were 60% less likely to have a flu-related medical visit and 52% less likely to have a flu-related hospitalization.
  • Vaccinated adults (18-64 years) were 52% less likely to have a flu-related medical visit and 40% less likely to have a flu-related hospitalization.
  • Vaccinated adults 65 years and older were 41% less likely to have a flu-related medical visit and 42% less likely to have a flu-related hospitalization.

CDC recommends that everyone 6 months and older who has not yet received a flu vaccine this season get vaccinated now.


Centers for Disease Control and Prevention

1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348
Questions or Problems  |  Unsubscribe

Update your preferences

  ...